Contract with Screen4 for COVID-19 antibody laboratory-based testing service
Omega Diagnostics Gp (ODX.L) Contract with Screen4
Omega Diagnostics Gp (ODX.L) UK-RTC statement on AbC-19TM rapid antibody test
Lateral flow test data shows potential for companion diagnostic to the Pfizer-BioNTech COVID-19 vaccine
Omega Diagnostics Gp (ODX.L) AbC-19TM rapid antibody test performance data
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes
Omega Diagnostics Gp (ODX.L) Director/PDMR Shareholding
Director/PDMR Shareholding – Exercise of Options and Total Voting Rights
Omega Diagnostics Gp (ODX.L) UK Government contract and trading update
UK Government manufacturing contract Board appointment & trading update
Omega Diagnostics Gp (ODX.L) Update re AbC-19 Rapid Test & antibody test service launch
Update re AbC-19TM Rapid Test
Omega Diagnostics Gp (ODX.L) Update re AbC-19 Rapid Test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today’s update from Abingdon Health plc (AIM: ABDX)
Omega Diagnostics Group PLC (ODX.L) Mologic CE Mark Rapid Antigen Test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, welcomes the news that Mologic Ltd (“Mologic”) has received CE Mark for it’s professional-use COVID-19
Omega Diagnostics Gp (ODX.L) UK-RTC Update
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the press release issued today by the UK Rapid Test Consortium (“UK-RTC”), of which
Omega Diagnostics Gp (ODX.L) Chinese approval for Food Detective® test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that the National Medical Products Administration (“NMPA”), formerly the China Food and Drug Administration,
Omega Diagnostics Gp (ODX.L) Trading update and notice of interim results
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces the following trading update in advance of releasing its interim results for the six
